blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1529527

EP1529527 - Valproic acid for a combination treatment of human cancers, tumor metastasis and minimal residual disease [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  28.09.2012
Database last updated on 14.06.2024
Most recent event   Tooltip28.09.2012Application deemed to be withdrawnpublished on 31.10.2012  [2012/44]
Applicant(s)For all designated states
TopoTarget Germany AG
Paul-Ehrlich-Strasse 42-44
60596 Frankfurt am Main / DE
[2006/02]
Former [2005/19]For all designated states
G2M Cancer Drugs AG
Paul-Ehrlich-Strasse 42-44
60596 Frankfurt am Main / DE
Inventor(s)01 / Groner, Bernd
Fichardstra e 48a
60322, Frankfurt am Main / DE
02 / Heinzel, Thorsten
Lotharstr. 34
55218 Ingelheim / DE
03 / Hentsch, Bernd
Gaissacherstrasse 20
81371 München / DE
04 / Wels, Winfried Stephan
Schweinfurter Weg 73
60599, Frankfurt / DE
05 / Herrlich, Peter A.
Vogelsang 8
76229, Karlsruhe / DE
06 / Minucci, Saverio
Via Sporting Mirasole 23, Int. 16 Opera Noverasco
20090, Milan / IT
07 / Pelicci, Pier Giuseppe
Via Emilia 10
20090, Opera / IT
08 / Göttlicher, Martin
Mareesstra e 1
80638, Munich / DE
 [2008/44]
Former [2006/02]01 / Groner, Bernd
Fichardstra e 48a
60322, Frankfurt am Main / DE
02 / Heinzel, Thorsten
Lotharstr. 34
55218 Ingelheim / DE
03 / Hentsch, Bernd
Gervinusstra e 8
60322, Frankfurt am Main / DE
04 / Wels, Winfried Stephan
Schweinfurter Weg 73
60599, Frankfurt / DE
05 / Herrlich, Peter A.
Vogelsang 8
76229, Karlsruhe / DE
06 / Minucci, Saverio
Via Sporting Mirasole 23, Int. 16 Opera Noverasco
20090, Milan / IT
07 / Pelicci, Pier Giuseppe
Via Emilia 10
20090, Opera / IT
08 / Göttlicher, Martin
Mareesstra e 1
80638, Munich / DE
Former [2005/38]01 / Groner, Bernd
Fichardstra e 48a
60322, Frankfurt am Main / DE
02 / Heinzel, Thorsten
Lotharstr. 34
55218 Ingelheim / DE
03 / Hentsch, Bernd
Gervinusstra e 8
60322, Frankfurt am Main / DE
04 / Wels, Winfried Stephan
Schweinfurter Weg 73
60599, Frankfurt / DE
05 / Herrlich, Peter A.
Vogelsang 8
76229, Karlsruhe / DE
06 / Minucci, Saverio
Via Don Minzoni 1
20090, Opera / IT
07 / Pelicci, Pier Giuseppe
Via Emilia 10
20090, Opera / IT
08 / Göttlicher, Martin
Mareesstra e 1
80638, Munich / DE
Former [2005/19]01 / Groner, Bernd
Fichardstra e 48a
60322, Frankfurt am Main / DE
02 / Heinzel, Thorsten
Libellenweg 10
60529, Frankfurt am Main / DE
03 / Hentsch, Bernd
Gervinusstra e 8
60322, Frankfurt am Main / DE
04 / Wels, Winfried Stephan
Schweinfurter Weg 73
60599, Frankfurt / DE
05 / Herrlich, Peter A.
Vogelsang 8
76229, Karlsruhe / DE
06 / Minucci, Saverio
Via Don Minzoni 1
20090, Opera / IT
07 / Pelicci, Pier Giuseppe
Via Emilia 10
20090, Opera / IT
08 / Göttlicher, Martin
Mareesstra e 1
80638, Munich / DE
Representative(s)Kalhammer, Georg
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
[N/P]
Former [2005/28]Kalhammer, Georg, Dr.
Lederer & Keller Patentanwälte Prinzregentenstrasse 16
80538 München / DE
Former [2005/19]Kalhammer, Georg, Dr.
Prinzregentenstrasse 16
80538 München / DE
Application number, filing date05101081.717.09.2002
[2005/19]
Priority number, dateEP2001012172218.09.2001         Original published format: EP 01121722
[2005/19]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1529527
Date:11.05.2005
Language:EN
[2005/19]
Type: A3 Search report 
No.:EP1529527
Date:25.05.2005
[2005/21]
Search report(s)(Supplementary) European search report - dispatched on:EP12.04.2005
ClassificationIPC:A61K31/19, A61P35/00
[2005/19]
CPC:
A61K45/06 (EP,US); A61K31/19 (EP,US); A61K31/20 (EP,US);
A61K31/28 (EP,US); A61K31/59 (EP,US); A61P35/00 (EP);
A61P43/00 (EP) (-)
C-Set:
A61K31/19, A61K2300/00 (EP,US);
A61K31/20, A61K2300/00 (US,EP);
A61K31/28, A61K2300/00 (US,EP);
A61K31/59, A61K2300/00 (US,EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SK,   TR [2005/19]
TitleGerman:Valproinsäure zur Kombinationsbehandlung von Krebs bei Menschen und zur Behandlung von Tumormetastasen und minimaler Resterkrankung[2005/19]
English:Valproic acid for a combination treatment of human cancers, tumor metastasis and minimal residual disease[2005/19]
French:Acide valproique pour la polythérapie du cancer humain et pour le traitement de la metastase de tumeurs et de la maladie residuelle imperceptible[2005/19]
Examination procedure28.10.2005Examination requested  [2005/52]
18.05.2006Despatch of a communication from the examining division (Time limit: M06)
28.11.2006Reply to a communication from the examining division
12.10.2007Despatch of a communication from the examining division (Time limit: M06)
08.04.2008Reply to a communication from the examining division
03.04.2012Application deemed to be withdrawn, date of legal effect  [2012/44]
01.06.2012Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2012/44]
Parent application(s)   TooltipEP02777129.4  / EP1427403
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20020777129) is  25.04.2005
Fees paidRenewal fee
14.02.2005Renewal fee patent year 03
30.08.2005Renewal fee patent year 04
31.08.2006Renewal fee patent year 05
27.07.2007Renewal fee patent year 06
31.03.2008Renewal fee patent year 07
28.08.2009Renewal fee patent year 08
30.09.2010Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
30.09.201110   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]EP0356332  (LIPOSOME CO INC [US]) [A] 1-14 * abstract ** page 12; example 15 *;
 [A]WO9606821  (AMERICAN BIOGENETIC SCIENCES [US], et al) [A] 1-14 * page 6, line 8 - page 7, line 13 * * page 11, line 1 - page 14, line 4 * * claim 30 *;
 [Y]US5728687  (BISSERY MARIE-CHRISTINE [FR]) [Y] 1-12 * claims 1-9 * * column 1, line 25 - line 60 *;
 [Y]  - MORI H ET AL, "EFFECT OF ALPHA-MERCAPTOPROPIONYLGLYCINE (ALPHA-MPG) AND SODIUM DIPROPYLACETATE (DPA) ON ANTIBODY FORMATION (IV)", MEDLINE, (197811), XP002166105 [Y] 1-14 * the whole document *
 [Y]  - HOLLAND, FREI, Cancer Medicine, e.5, HAMILTON, LONDON, B.C. DECKER INC., (2000), XP002320152 [Y] 1-14 * page 612 - page 698 *
 [X]  - JANSMAN F G A ET AL, "Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer", DRUG SAFETY 2000 NEW ZEALAND, (2000), vol. 23, no. 4, ISSN 0114-5916, pages 255 - 278, XP008044019 [X] 1-14 * table 5 * * page 269, column R, paragraph 2 *

DOI:   http://dx.doi.org/10.2165/00002018-200023040-00001
 [A]  - AIKEN T C ET AL, "A POSSIBLE ANTI-EMETIC ROLE FOR SODIUM VALPROATE CIN CYTOTOXIC CHEMOTHERAPY", BRITISH JOURNAL OF HAEMATOLOGY, OXFORD, GB, (199504), vol. 4, no. 89, ISSN 0007-1048, pages 903 - 904, XP008004839 [A] 1-12 * abstract * * page 904, column R, paragraph 3 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.